Device Trial Radar · NCT04015219
Management of Signs and Symptoms Associated With Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Jul 18, 2018
Primary completion
Oct 5, 2020
Study completion Oct 5, 2020
Sponsor
- Lead sponsor
- BioTissue Holdings, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 10, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective randomized, and controlled study to compare the effectiveness of PROKERA® SLIM plus standard of care (SOC) in the PROKERA® SLIM Arm to SOC alone in the Control Arm. Subjects presenting with moderate DED defined as corneal fluorescein staining score of ≥ 3 points out of 9 will be recruited.
Conditions
- Dry Eye Syndromes
Interventions
Self retained cryopreserved amniotic membraneDevice
PROKERA SLIM
lifitegrast ophthalmic solutionOther
Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal Fluorescein StainingTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center of Excellence in Eye Care
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.